PSIL vs. SBIO

Last updated Jun 23, 2026

PSIL (AdvisorShares Psychedelics ETF) and SBIO (ALPS Medical Breakthroughs ETF) are both Health & Biotech Equities funds. PSIL is actively managed, while SBIO is passively managed. Over the past 3 years, PSIL returned 10.23%/yr vs 23.70%/yr for SBIO. At a 0.50 correlation, their price movements are largely independent. PSIL charges 1.00%/yr vs 0.50%/yr for SBIO.

Performance

PSIL vs. SBIO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in AdvisorShares Psychedelics ETF (PSIL) and ALPS Medical Breakthroughs ETF (SBIO). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, PSIL achieves a 24.34% return, which is significantly higher than SBIO's 14.53% return.

PSIL

• 1D: 6.27%
• 1M: 1.04%
• YTD: 24.34%
• 6M: 22.35%
• 1Y: 54.09%
• 3Y*: 10.23%
• 5Y*: —
• 10Y*: —

SBIO

• 1D: 6.44%
• 1M: 10.06%
• YTD: 14.53%
• 6M: 12.40%
• 1Y: 95.53%
• 3Y*: 23.70%
• 5Y*: 4.51%
• 10Y*: 11.14%

*Multi-year figures are annualized to reflect compound growth (CAGR)

PSIL vs. SBIO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
PSIL AdvisorShares Psychedelics ETF	24.34%	74.55%	-19.50%	-25.12%	-67.24%	-42.72%
SBIO ALPS Medical Breakthroughs ETF	14.53%	55.07%	3.81%	8.68%	-28.08%	-8.86%

Correlation

The correlation between PSIL and SBIO is 0.58, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.58
Correlation (3Y) Calculated over the trailing 3-year period	0.49
Correlation (All Time) Calculated using the full available price history since Sep 16, 2021	0.50

The correlation between PSIL and SBIO has been stable across timeframes, ranging from 0.49 to 0.58 - a consistent structural relationship.

PSIL vs. SBIO - Sectors Allocation Comparison

Sectors	PSIL	SBIO
Healthcare	100.0%	100.0%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Financial Services	-	-0.0%
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

PSIL vs. SBIO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PSIL

PSIL Risk / Return Rank: 40
PSIL Sharpe Ratio Rank: 37
PSIL Sortino Ratio Rank: 36
PSIL Omega Ratio Rank: 36
PSIL Calmar Ratio Rank: 56
PSIL Martin Ratio Rank: 37

SBIO

SBIO Risk / Return Rank: 91
SBIO Sharpe Ratio Rank: 93
SBIO Sortino Ratio Rank: 90
SBIO Omega Ratio Rank: 83
SBIO Calmar Ratio Rank: 95
SBIO Martin Ratio Rank: 91

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PSIL vs. SBIO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for AdvisorShares Psychedelics ETF (PSIL) and ALPS Medical Breakthroughs ETF (SBIO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	PSIL	SBIO	Difference
Sharpe ratio: Return per unit of total volatility	1.28	3.16	-1.88
Sortino ratio: Return per unit of downside risk	1.83	4.03	-2.20
Omega ratio: Gain probability vs. loss probability	1.23	1.48	-0.25
Calmar ratio: Return relative to maximum drawdown	2.67	7.59	-4.92
Martin ratio: Return relative to average drawdown	5.56	21.16	-15.60

PSIL vs. SBIO - Sharpe Ratio Comparison

The current PSIL Sharpe Ratio is 1.28, which is lower than the SBIO Sharpe Ratio of 3.16. The chart below compares the historical Sharpe Ratios of PSIL and SBIO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

PSIL vs. SBIO - Drawdown Comparison

The maximum PSIL drawdown since its inception was -92.72%, which is greater than SBIO's maximum drawdown of -63.06%. Use the drawdown chart below to compare losses from any high point for PSIL and SBIO.

Drawdown Indicators

	PSIL	SBIO	Difference
Max Drawdown Largest peak-to-trough decline	-92.72%	-63.06%	-29.66%
Max Drawdown (1Y) Largest decline over 1 year	-20.38%	-12.66%	-7.72%
Max Drawdown (3Y) Largest decline over 3 years	-64.62%	-42.44%	-22.18%
Max Drawdown (5Y) Largest decline over 5 years	—	-53.10%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-63.06%	—
Current Drawdown Current decline from peak	-75.81%	-4.33%	-71.48%
Average Drawdown Average peak-to-trough decline	-76.71%	-28.37%	-48.34%
Ulcer Index Depth and duration of drawdowns from previous peaks	9.86%	4.53%	+5.33%

Volatility

PSIL vs. SBIO - Volatility Comparison

AdvisorShares Psychedelics ETF (PSIL) has a higher volatility of 13.08% compared to ALPS Medical Breakthroughs ETF (SBIO) at 11.14%. This indicates that PSIL's price experiences larger fluctuations and is considered to be riskier than SBIO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	PSIL	SBIO	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.08%	11.14%	+1.94%
Volatility (6M) Calculated over the trailing 6-month period	28.55%	23.77%	+4.78%
Volatility (1Y) Calculated over the trailing 1-year period	42.51%	30.46%	+12.05%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	63.01%	33.75%	+29.26%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	63.01%	33.23%	+29.78%

PSIL vs. SBIO - Expense Ratio Comparison

PSIL has a 1.00% expense ratio, which is higher than SBIO's 0.50% expense ratio.

Dividends

PSIL vs. SBIO - Dividend Comparison

PSIL's dividend yield for the trailing twelve months is around 8.04%, while SBIO has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017
PSIL AdvisorShares Psychedelics ETF	8.04%	10.95%	1.49%	0.24%	2.91%	0.00%	0.00%	0.00%	0.00%	0.00%
SBIO ALPS Medical Breakthroughs ETF	0.00%	0.00%	3.55%	0.22%	0.00%	0.00%	0.00%	0.04%	2.79%	1.77%

Frequently Asked Questions

Can I hold both PSIL and SBIO in my portfolio?

PSIL and SBIO have a correlation of 0.58, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, PSIL or SBIO?

PSIL has higher volatility (13.08%) compared to SBIO (11.14%). In terms of maximum drawdown, PSIL dropped -92.72% vs SBIO's -63.06%.

Which ETF is better, PSIL or SBIO?

On 3-year performance, SBIO leads with 23.70% vs 10.23% for PSIL. On fees, SBIO is cheaper at 0.50% per year. On volatility, SBIO has been the lower-risk option at 11.14%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, PSIL or SBIO?

Over the 3-year period, SBIO has performed better with a 23.70% return vs 10.23%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, PSIL or SBIO?

SBIO is cheaper with a 0.50% expense ratio, compared with 1.00% for PSIL.

Which ETF pays a higher dividend yield, PSIL or SBIO?

PSIL has the higher dividend yield at 8.04%, compared with 0.00% for SBIO.

What is the main difference between PSIL and SBIO?

They also come from different issuers: AdvisorShares and SS&C. Their fees differ too: 1.00% for PSIL and 0.50% for SBIO.

Which has better risk-adjusted returns?

SBIO currently has the higher Sharpe Ratio (3.16 vs 1.28), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.